News | October 16, 2023
ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Lokavant provides clinical trial intelligence
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Kivo’s expanded platform brings compliant collaboration and intelligent process automation to emerging Regulatory, Clinical and Quality teams
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Subscribe To Our Newsletter & Stay Updated
